If you’re looking at treatment options for heart failure, you may want to learn more about Entresto (sacubitril/valsartan). It’s a prescription drug used to treat ...

Entresto (sacubitril/valsartan) is a brand-name prescription medication and is approved it to treat certain types of heart failure in adults. Additionally, Entresto ...

Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a ...

Entresto is a brand-name prescription medication containing sacubitril and valsartan. The FDA approved generic versions of Entresto in May 2024, and the drug was launched in July 2025. According to ...

Novartis believes its heart failure drug Entresto's clinical data, commercial infrastructure and recognition among cardiologists can help it fend off potential competition from Eli Lilly and ...

Novartis' drug, which combines sacubitril and valsartan, is the first to directly treat patients with heart failure with preserved ejection fraction. FDA on Tuesday granted Entresto, a combination of ...

Novartis AG NVS announced results from a post-hoc analysis from the PARADIGM-HF trial on cardiovascular drug Entresto. The results were published in JAMA Cardiology. The results demonstrated that ...

Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing ...

Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations, claiming that the move will ...

A new suit against Novartis comes as the Swiss pharma is trying to fend off several Entresto generic contenders with lawsuits. (Novartis) Novartis is already suing a long list of generics producers ...

Best practice around value-based contracting, which involves tying reimbursement for drugs (or devices or digital health tools, etc.) to proof that they deliver improved outcomes or lower treatment ...

New Trump tariffs on pharmaceuticals could double the cost of common prescription drugs, raising prices for medications like ...